Article Text

other Versions

PDF
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy

Statistics from Altmetric.com

This is a PDF-only article. The first page of the PDF of this article appears below.

PDF extract preview
  • Competing interests: MS, advisor and speakers bureau for Roche.
    EMY, Honoraria for lectures sponsored by Roche and Schering Plough; Advisor to Roche; Unrestricted research grants from Roche, Schering Plough, Fujisawa, Pfizer, GlaxoSmithKline; Investigator in trials sponsored by Roche, Schering Ploughm Human Genome Sciences, Idenix, Microgenix, Fujisawa, Novartis, Wyeth.
    MD, no conflicts of interest to declare.
    MK, unrestricted research grants from Roche, Schering Plough.
    VGB, no conflicts of interest to declare.
    KP, no conflicts of interest to declare.
    FA, no conflicts of interest to declare.
    KK, no conflicts of interest to declare.
    SS, Roche employee.
    SSL, research grants from Roche, speakers bureau and consulting for Roche.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.